Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2022

View Archived Issues

PILA identified as lncRNA that enhances NF-kappaB signaling and osteoarthritis

CNPY4 knockout embryos exhibit hedgehog signaling hyperactivation-driven defects

ATV-006, orally bioavailable antiviral candidate against SARS-CoV-2

Integral BioSciences patents ENPP1 inhibitors

Newave Pharmaceutical discloses new BTK inhibitors

Bivalent Epstein-Barr nanoparticle vaccine protects against infection in mice

Evusheld retains neutralization activity against SARS-CoV-2 Omicron BA.4 and BA.5 variants

Rhizen Pharmaceuticals divulges new PARP inhibitors

New EGFR inhibitors identified at Lengo Therapeutics

U.S. researchers present new NR1D2 agonists

CureVac and myNEO enter research and option agreement toward development of mRNA cancer vaccines

HotSpot and Excelra partner to support HotSpot's allosteric inhibitor candidate pipeline

Ellipses Pharma licenses rights to SunRock's bifunctional HER3:TRAIL fusion protein

PAI-1-TFT therapy shows promise for treating pleural empyema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...